SK77096A3 - 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adreno-receptor agonists - Google Patents

6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adreno-receptor agonists Download PDF

Info

Publication number
SK77096A3
SK77096A3 SK770-96A SK77096A SK77096A3 SK 77096 A3 SK77096 A3 SK 77096A3 SK 77096 A SK77096 A SK 77096A SK 77096 A3 SK77096 A3 SK 77096A3
Authority
SK
Slovakia
Prior art keywords
unsubstituted
compounds
quinoline
alkanyl
alpha
Prior art date
Application number
SK770-96A
Other languages
English (en)
Slovak (sk)
Inventor
Thomas L Cupps
Peter J Maurer
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/326,564 external-priority patent/US5578607A/en
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of SK77096A3 publication Critical patent/SK77096A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SK770-96A 1993-12-17 1994-12-15 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adreno-receptor agonists SK77096A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16934393A 1993-12-17 1993-12-17
US08/326,564 US5578607A (en) 1993-12-17 1994-10-20 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
PCT/US1994/014293 WO1995016683A1 (fr) 1993-12-17 1994-12-15 Composes de 6-(2-imidazolinylamino)quinoline utiles en tant qu'agonistes des adrenocepteurs alpha-2

Publications (1)

Publication Number Publication Date
SK77096A3 true SK77096A3 (en) 1997-02-05

Family

ID=26864975

Family Applications (1)

Application Number Title Priority Date Filing Date
SK770-96A SK77096A3 (en) 1993-12-17 1994-12-15 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adreno-receptor agonists

Country Status (23)

Country Link
US (1) US5739148A (fr)
EP (1) EP0736020B1 (fr)
JP (1) JPH09511483A (fr)
CN (1) CN1046718C (fr)
AT (1) ATE192150T1 (fr)
AU (1) AU699041B2 (fr)
BR (1) BR9408335A (fr)
CA (1) CA2179264C (fr)
CZ (1) CZ285481B6 (fr)
DE (1) DE69424183T2 (fr)
DK (1) DK0736020T3 (fr)
ES (1) ES2146307T3 (fr)
FI (1) FI962491A (fr)
GR (1) GR3033515T3 (fr)
HK (1) HK1013072A1 (fr)
HU (1) HU217841B (fr)
NO (1) NO308662B1 (fr)
NZ (1) NZ333370A (fr)
PL (1) PL180392B1 (fr)
PT (1) PT736020E (fr)
SG (1) SG55141A1 (fr)
SK (1) SK77096A3 (fr)
WO (1) WO1995016683A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
WO2005089515A2 (fr) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Procedes de traitement des synucleinopathies
WO2005089502A2 (fr) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Traitement des synucleinopathies
WO2005089504A2 (fr) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Procedes pour le traitement de synucleinopathies
EP1732549A4 (fr) * 2004-03-18 2009-11-11 Brigham & Womens Hospital Procedes pour le traitement de synucleinopathies
WO2005117904A2 (fr) * 2004-04-14 2005-12-15 Gilead Sciences, Inc. Analogues de phosphonate de composes inhibiteurs de l'integrase du vih
AU2006311577B2 (en) 2005-11-09 2013-02-07 Zalicus Inc. Methods, compositions, and kits for the treatment of medical conditions
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
JP2012508768A (ja) * 2008-11-13 2012-04-12 リンク・メディスン・コーポレーション アザキノリノン誘導体及びその使用
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
RU2014106364A (ru) * 2011-07-25 2015-08-27 Аллерган, Инк. Производные n-(имидазолидин-2-илидин)хинолина как модуляторы адренергических рецепторов альфа-2

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4029792A (en) * 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
US4036976A (en) * 1973-04-05 1977-07-19 Sandoz, Inc. Substituted imidazolinylamino-indazoles
US4217356A (en) * 1975-08-22 1980-08-12 Sandoz Ltd. 2-Imidazolinylamino-2,1,3-benzothiadiazoles
US4398028A (en) * 1977-01-14 1983-08-09 Sandoz Ltd. Bicyclic heterocyclic amino derivatives
DE3071229D1 (en) * 1979-08-23 1985-12-19 Beecham Group Plc Anti-diarrhoea veterinary composition
US4436913A (en) * 1980-09-05 1984-03-13 Siegfried Aktiengesellschaft 1H- and 2H- indazole derivatives
FR2638356A1 (fr) * 1988-10-28 1990-05-04 Anben Nouveaux derives de la 2-arylimino-imidazolidine pour diminuer la pression intra-oculaire et traiter le glaucome
US5021410A (en) * 1989-05-22 1991-06-04 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5281591A (en) * 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5180721A (en) * 1989-05-22 1993-01-19 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5231096A (en) * 1989-10-12 1993-07-27 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5021416A (en) * 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5091528A (en) * 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents

Also Published As

Publication number Publication date
WO1995016683A1 (fr) 1995-06-22
NZ333370A (en) 2001-03-30
CA2179264C (fr) 1999-05-18
EP0736020A1 (fr) 1996-10-09
PL180392B1 (pl) 2001-01-31
HUT76277A (en) 1997-07-28
CN1137793A (zh) 1996-12-11
DE69424183T2 (de) 2001-02-15
PL315060A1 (en) 1996-09-30
DE69424183D1 (de) 2000-05-31
NO308662B1 (no) 2000-10-09
FI962491A0 (fi) 1996-06-14
CZ285481B6 (cs) 1999-08-11
HK1013072A1 (en) 1999-08-13
HU217841B (hu) 2000-04-28
HU9601659D0 (en) 1996-08-28
CZ175396A3 (en) 1996-11-13
NO962536L (no) 1996-08-02
DK0736020T3 (da) 2000-08-07
CA2179264A1 (fr) 1995-06-22
PT736020E (pt) 2000-10-31
NO962536D0 (no) 1996-06-14
AU1306395A (en) 1995-07-03
EP0736020B1 (fr) 2000-04-26
US5739148A (en) 1998-04-14
FI962491A (fi) 1996-07-26
BR9408335A (pt) 1997-08-19
JPH09511483A (ja) 1997-11-18
ATE192150T1 (de) 2000-05-15
ES2146307T3 (es) 2000-08-01
GR3033515T3 (en) 2000-09-29
CN1046718C (zh) 1999-11-24
SG55141A1 (en) 1998-12-21
AU699041B2 (en) 1998-11-19

Similar Documents

Publication Publication Date Title
CA2179008C (fr) Derives de 5-(2-imidazolinylamino)benzimidazole, leur preparation et leur utilisation en tant qu'agonistes de l'adrenocepteur alpha-2
EP0735877B1 (fr) Composes de 6-(2-imidazolinylamino)quinoxaline utilises en tant qu'agonistes de l'adrenocepteur alpha-2
US5576437A (en) 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists
SK77096A3 (en) 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adreno-receptor agonists
US5578607A (en) 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
RU2161967C2 (ru) Соединения 7-(2-имидазолиниламино) хинолина, пригодные в качестве агонистов альфа-2-адренорецептора